AlTi Global, Inc. to Participate in Barclays Global Financial Services Conference
AlTi Global, Inc. to Participate in Barclays Global Financial Services Conference
AlTi Global, Inc. (NASDAQ: ALTI) (“AlTi” or the “Company”), a leading independent global wealth and alternatives manager with $72 billion in combined assets, today announced that Michael Tiedemann, Chief Executive Officer, and Stephen Yarad, Chief Financial Officer, will participate in and host meetings at the Barclays Global Financial Services Conference in New York on Wednesday, September 11th.
About AlTi
AlTi is a leading independent global wealth and alternatives manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. AlTi’s comprehensive offering is underscored by a commitment to impact or values-aligned investing and generating a net positive impact through its business activities. The firm currently manages or advises on $72 billion in combined assets and has an expansive network with approximately 430 professionals across three continents. For more information, please visit us at www.alti-global.com.
Lily Arteaga
Head of Investor Relations
AlTi Global, Inc.
investor@alti-global.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827475003/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks